Immunosuppression in hepatitis C virus-infected patients after kidney transplantation

Area of Science:

• Nephrology
• Virology
• Immunology

Background:

• Hepatitis C virus (HCV) infection is more prevalent in kidney transplant recipients than the general population.
• Kidney transplantation is the preferred treatment for end-stage kidney disease in HCV-infected individuals, despite reduced survival rates.
• Immunosuppression significantly impacts HCV replication and disease progression post-transplant.

Purpose of the Study:

• To review and discuss optimal immunosuppressive strategies for kidney transplant recipients with HCV infection.
• To highlight the challenges in managing immunosuppression in this patient population.

Main Methods:

• Literature review and synthesis of current evidence on immunosuppression in HCV-infected kidney transplant recipients.
• Analysis of the impact of induction therapy, corticosteroid withdrawal, and calcineurin inhibitors on HCV outcomes.

Main Results:

• Induction therapy, particularly short-course, may be beneficial for HCV-infected kidney transplant recipients.
• Corticosteroid withdrawal can be considered in patients with comorbidities like diabetes or osteoporosis.
• Optimal calcineurin inhibitor choice requires further investigation due to limited controlled trials.

Conclusions:

• Individualizing immunosuppressive regimens based on clinical parameters beyond HCV status is essential.
• Prospective controlled studies are needed to establish definitive optimal immunosuppressive protocols for HCV-infected kidney transplant recipients.